Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Regression Models and Life-Tables

1992 • 27,454 citations

Regression Models and Life-Tables

1972 • 27,145 citations

Nonparametric Estimation from Incomplete Observations

1958 • 7,673 citations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 • 2,777 citations

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

1997 • 1,652 citations

Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

1998 • 914 citations

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

1999 • 878 citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 • 747 citations

Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma

1991 • 712 citations

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

2000 • 695 citations

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

1999 • 653 citations

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

1997 • 638 citations

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

2000 • 576 citations

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

2001 • 533 citations

Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial

1997 • 464 citations

Follicular lymphoma: prognostic factors for response and survival.

1986 • 444 citations

Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals

1995 • 426 citations

Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma

1999 • 360 citations

All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment

1991 • 347 citations

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.

1995 • 344 citations

Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma

1993 • 340 citations

Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab

1999 • 296 citations

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.

1994 • 267 citations

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.

1994 • 244 citations

Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies

2000 • 208 citations

High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up

2000 • 192 citations

Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma

1999 • 188 citations

Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases

2000 • 186 citations

Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow

1994 • 182 citations

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

2000 • 174 citations

Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting

1997 • 166 citations

The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas

1998 • 165 citations

Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non- Hodgkin's lymphoma

1994 • 157 citations

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

1997 • 154 citations

The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma.

1991 • 153 citations

Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma

1999 • 139 citations

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program

2023 • 121 citations

A UK multicentre phase II study of rituximab (chimaeric anti‐CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

2000 • 117 citations

CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.

1999 • 101 citations

Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion

1992 • 94 citations

Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma.

1994 • 91 citations

Monoclonal antibody-based therapies for hematologic malignancies.

1998 • 82 citations

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

2001 • 70 citations

Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma

2001 • 67 citations

Rituximab (IDEC-C2B8): Validation of a Sensitive Enzyme-Linked Immunoassay Applied to a Clinical Pharmacokinetic Study

2000 • 64 citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 • 60 citations

Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.

1999 • 48 citations

t(14;18), a journey to eternity

1997 • 37 citations

High Dose Therapy and Autologous Stem Cell Transplantation in Follicular non-Hodgkin's Lymphoma

1998 • 19 citations

Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma

1993 • 19 citations

Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategy

1999 • 17 citations

Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow

1994 • 16 citations

Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non- Hodgkin's lymphoma

1994 • 6 citations